{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,6]],"date-time":"2026-03-06T19:51:17Z","timestamp":1772826677150,"version":"3.50.1"},"reference-count":56,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2021,6,17]],"date-time":"2021-06-17T00:00:00Z","timestamp":1623888000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Oncol."],"abstract":"<jats:sec><jats:title>Introduction<\/jats:title><jats:p>This report investigates the impact of systemic treatments (chemotherapy or immunotherapy) with(out) loco-regional radiotherapy, on HRQoL, toxicity and neurocognitive functioning (NCF) in locally advanced and metastatic non-small cell lung cancer patients enrolled in the PRO-Long study.<\/jats:p><\/jats:sec><jats:sec><jats:title>Materials and Methods<\/jats:title><jats:p>Data on patient-reported HRQoL and fourteen toxicities was collected, while NCF was tested, up to one-year post-treatment. HRQoL was assessed using the European Organisation for Research and Treatment of Cancer QLQ-C30. Lung cancer, treatment and neuro-psychological related toxicities were scored with the Patient-Reported Outcomes version of the Common Terminology Criteria for Adverse Events. NCF was evaluated with six neurocognitive tests. Mixed model analyses were conducted to determine statistical significance (p = .01). Meaningful clinical important differences (MCIDs) were applied for changes in HRQoL and NCF data, while toxicities were compared to baseline values.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>In total, 50 patients were enrolled. Overall HRQoL (p = .357) nor its domains (physical, p = .643; role, p = .069; emotional, p = .254; cognitive, p = 494; social, p = .735) changed significantly over time. Meaningful improvements in overall HRQoL were seen in 22, 38 and 39% and deteriorations in 22, 5 and 28% of patients at 2\u20133, 6 and 12 months respectively post-treatment. Overall toxicity (p = .007), lack of appetite (p = .001), nausea (p = .004) and dysphagia (p = .000) significantly decreased over time. Treatment caused acute toxicity, such as dyspnoea (45%) and memory problems (42%), but also alleviated pre-existing symptoms, including lack of appetite (32%), anxiety (29%) and depression (28%) at 2\/3 months. The NCF domains of visual memory (p = .000) and cognitive processing speed (p = .000) showed significant improvements over time. In terms of MCIDs, at 2\u20133 months (18%) and 6 months (15%), verbal memory was particularly impacted; at 12 months, visual memory (18%) and executive function (18%) deteriorated primarily.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusion<\/jats:title><jats:p>The results suggest that therapy has no significant negative impact on overall HRQoL, its domains, and NCF. About one-third of patients reported a meaningful improved HRQoL at 1 year post-treatment. Treatment caused toxicity, but also alleviated pre-existing symptoms.<\/jats:p><\/jats:sec>","DOI":"10.3389\/fonc.2021.685605","type":"journal-article","created":{"date-parts":[[2021,6,17]],"date-time":"2021-06-17T08:18:38Z","timestamp":1623917918000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":8,"title":["Real Life Data on Patient-Reported Outcomes and Neuro-Cognitive Functioning of Lung Cancer Patients: The PRO-Long Study"],"prefix":"10.3389","volume":"11","author":[{"given":"Lotte","family":"Van Der Weijst","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Veerle","family":"Surmont","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wim","family":"Schrauwen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yolande","family":"Lievens","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1965","published-online":{"date-parts":[[2021,6,17]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"394","DOI":"10.3322\/caac.21492","article-title":"Global Cancer Statistics 2018: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries","volume":"68","author":"Bray","year":"2018","journal-title":"CA: A Cancer J Clin"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2009.26.2543","article-title":"Meta-Analysis of Concomitant Versus Sequential Radiochemotherapy in Locally Advanced Non-Small-Cell Lung Cancer","volume":"28","author":"Aup\u00e9rin","year":"2010","journal-title":"J Clin Oncol"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdq207","article-title":"Early Stage and Locally Advanced (Non-Metastatic) Non-Small-Cell Lung Cancer: ESMO Clinical Practice Guidelines for Diagnosis, Treatment and Follow-Up","volume":"21","author":"Crin\u00f2","year":"2010","journal-title":"Ann Oncol"},{"key":"B4","doi-asserted-by":"publisher","first-page":"498","DOI":"10.1016\/j.cllc.2020.06.010","article-title":"Immune-Related Adverse Events of Pembrolizumab in a Large Real-World Cohort of Patients With NSCLC With a PD-L1 Expression \u2265 50% and Their Relationship With Clinical Outcomes","volume":"21","author":"Cortellini","year":"2020","journal-title":"Clin Lung Cancer"},{"key":"B5","doi-asserted-by":"publisher","first-page":"50","DOI":"10.1016\/j.annonc.2019.10.008","article-title":"Adverse Event Profile for Immunotherapy Agents Compared With Chemotherapy in Solid Organ Tumors: A Systematic Review and Meta-Analysis of Randomized Clinical Trials","volume":"31","author":"Magee","year":"2020","journal-title":"Ann Oncol"},{"key":"B6","doi-asserted-by":"publisher","first-page":"114","DOI":"10.1016\/j.cllc.2019.06.006","article-title":"Impact of Lung Cancer Treatment on Cognitive Functioning","volume":"21","author":"van de Kamp","year":"2020","journal-title":"Clin Lung Cancer"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1016\/j.critrevonc.2017.09.014","article-title":"Systematic Literature Review of Health-Related Quality of Life in Locally-Advanced Non-Small Cell Lung Cancer: Has It Yet Become State-of-the-Art","volume":"119","author":"van der Weijst","year":"2017","journal-title":"Crit Rev Oncol\/Hematol"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2019.00715","article-title":"Health-Related Quality of Life in Advanced Non-Small Cell Lung Cancer: A Methodological Appraisal Based on a Systematic Literature Review","volume":"9","author":"Van Der Weijst","year":"2019","journal-title":"Front Oncol"},{"key":"B9","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1016\/j.lungcan.2019.10.022","article-title":"Quality of Life Analysis in Lung Cancer: A Systematic Review of Phase III Trials Published Between 2012 and 2018","volume":"139","author":"Reale","year":"2020","journal-title":"Lung Cancer"},{"key":"B10","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1177\/1758834010395342","article-title":"Health-Related Quality of Life and Cancer Clinical Trials","volume":"3","author":"Osoba","year":"2011","journal-title":"Ther Adv Med Oncol"},{"key":"B11","doi-asserted-by":"publisher","first-page":"86","DOI":"10.1186\/1741-7015-9-86","article-title":"Measuring Patient-Reported Outcomes: Moving Beyond Misplaced Common Sense to Hard Science","volume":"9","author":"McKenna","year":"2011","journal-title":"BMC Med"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1016\/j.socscimed.2004.06.022","article-title":"The Use of Patient Reported Outcome Measures in Routine Clinical Practice: Lack of Impact or Lack of Theory","volume":"60","author":"Greenhalgh","year":"2005","journal-title":"Soc Sci Med"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1016\/j.suponc.2011.11.002","article-title":"Central Nervous System Complications of Cancer Therapy","volume":"10","author":"Rinne","year":"2012","journal-title":"J Support Oncol"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(04)01465-2","article-title":"What is the Effect of Systemic Anticancer Treatment on Cognitive Function","volume":"5","author":"Minisini","year":"2004","journal-title":"Lancet Oncol"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1002\/cam4.174","article-title":"Association Between Adjuvant Regional Radiotherapy and Cognitive Function in Breast Cancer Patients Treated With Conservation Therapy","volume":"3","author":"Shibayama","year":"2014","journal-title":"Cancer Med"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1093\/jnci\/djz168","article-title":"Potential Effect of Immunotherapy Agents on Cognitive Function in Cancer Patients","volume":"112","author":"Joly","year":"2020","journal-title":"J Natl Cancer Inst"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.1016\/S0895-4356(96)00428-3","article-title":"Validation of the EORTC Qlq-C30 Quality of Life Questionnaire Through Combined Qualitative and Quantitative Assessment of Patient-Observer Agreement","volume":"50","author":"Groenvold","year":"1997","journal-title":"J Clin Epidemiol"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.1093\/jnci\/85.5.365","article-title":"The European Organistaion for Research and Treatment of Cancer Qlq-C30: A Quality-of-Life Instrument for Use in International Clinical Trials in Oncology","volume":"85","author":"Aaronson","year":"1993","journal-title":"J Natl Cancer Inst"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejca.2010.08.021","article-title":"The EORTC Qlq-LC13: A Modular Supplement to the EORTC Core Quality of Life Questionnaire (Qlq-C30) for Use in Lung Cancer Clinical Trials. EORTC Study Group on Quality of Life","author":"Bergman","year":"1994","journal-title":"Eur J Cancer"},{"key":"B20","doi-asserted-by":"publisher","first-page":"dju244","DOI":"10.1093\/jnci\/dju244","article-title":"Development of the National Cancer Institute\u2019s Patient-Reported Outcomes Version of the Common Terminology Criteria for Adverse Events (PRO-CTCAE)","volume":"106","author":"Basch","year":"2014","journal-title":"J Natl Cancer Inst"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijrobp.2011.03.015","article-title":"Standardized Total Average Toxicity Score: A Scale- and Grade-Independent Measure of Late Radiotherapy Toxicity to Facilitate Pooling of Data From Different Studies","volume":"82","author":"Barnett","year":"2012","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejca.2017.06.025","article-title":"A Systematic Review of the Quality of Statistical Methods Employed for Analysing Quality of Life Data in Cancer Randomised Controlled Trials","volume":"83","author":"Hamel","year":"2017","journal-title":"Eur J Cancer"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2009.23.7420","article-title":"Quality of Life Supersedes the Classic Prognosticators for Long-Term Survival in Locally Advanced Non-Small-Cell Lung Cancer: An Analysis of RTOG 9801","volume":"27","author":"Movsa","year":"2009","journal-title":"J Clin Oncol"},{"key":"B24","doi-asserted-by":"publisher","first-page":"353","DOI":"10.1186\/1471-2407-11-353","article-title":"Quality of Life Assessment as a Predictor of Survival in Non-Small Cell Lung Cancer","volume":"11","author":"Braun","year":"2011","journal-title":"BMC Cancer"},{"key":"B25","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1177\/1533317520960868","article-title":"Observed Physical Function Is Associated With Better Cognition Among Elderly Adults: The Adventist Health Study-2","volume":"35","author":"Gatto","year":"2020","journal-title":"Am J Alzheimer\u2019s Dis Other Demen"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.1097\/NCC.0b013e3181f9a040","article-title":"Coping, Quality of Life, Depression, and Hopelessness in Cancer Patients in a Curative and Palliative, End-of-Life Care Setting","volume":"34","author":"Van Laarhoven","year":"2011","journal-title":"Cancer Nurs"},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.1007\/BF02838622","article-title":"Effect of Chemotherapy on Quality of Life in Patients With Non-Small Cell Lung Cancer","volume":"22","author":"Mannion","year":"2014","journal-title":"Support Care Cancer"},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.1586\/erp.11.57","article-title":"Impact of Response Shift on Longitudinal Quality-of-Life Assessment in Cancer Clinical Trials","volume":"11","author":"Hamidou","year":"2011","journal-title":"Expert Rev Pharmacoecon Outcomes Res"},{"key":"B29","doi-asserted-by":"publisher","DOI":"10.1080\/0284186X.2019.1634835","article-title":"Patient-Reported Lung Symptoms and Quality of Life Before and After Radiation Therapy for Non-Small Cell Lung Cancer: Correlation With Radiation Pneumonitis and Functional Imaging","volume":"58","author":"Farr","year":"2019","journal-title":"Acta Oncol"},{"key":"B30","doi-asserted-by":"publisher","DOI":"10.1016\/j.radonc.2008.10.006","article-title":"Dyspnea Evolution After High-Dose Radiotherapy in Patients With Non-Small Cell Lung Cancer","volume":"91","author":"De Ruysscher","year":"2009","journal-title":"Radiother Oncol"},{"key":"B31","doi-asserted-by":"publisher","first-page":"8","DOI":"10.1016\/S0885-3924(00)00258-X","article-title":"Dyspnea in Cancer Patients: Prevalence and Associated Factors","volume":"21","author":"Dudgeon","year":"2001","journal-title":"J Pain Symptom Manage"},{"key":"B32","doi-asserted-by":"publisher","DOI":"10.1016\/j.apnu.2013.12.005","article-title":"Memory and Cancer: A Review of the Literature","volume":"28","author":"McDougall","year":"2014","journal-title":"Arch Psychiatr Nurs"},{"key":"B33","doi-asserted-by":"publisher","DOI":"10.1016\/j.lungcan.2016.08.002","article-title":"Scan-Associated Distress in Lung Cancer: Quantifying the Impact of \"Scanxiety\"","volume":"100","author":"Bauml","year":"2016","journal-title":"Lung Cancer"},{"key":"B34","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2015.63.0830","article-title":"Symptom Monitoring With Patient-Reported Outcomes During Routine Cancer Treatment: A Randomized Controlled Trial","volume":"34","author":"Basch","year":"2016","journal-title":"J Clin Oncol"},{"key":"B35","doi-asserted-by":"publisher","first-page":"59","DOI":"10.1080\/07347332.2013.855963","article-title":"Lung Cancer Stigma, Anxiety, Depression, and Quality of Life","volume":"32","author":"Brown Johnson","year":"2014","journal-title":"Null"},{"key":"B36","doi-asserted-by":"publisher","DOI":"10.1186\/1756-0500-4-519","article-title":"Interaction of Hope and Optimism With Anxiety and Depression in a Specific Group of Cancer Survivors: A Preliminary Study","volume":"4","author":"Rajandram","year":"2011","journal-title":"BMC Res Notes"},{"key":"B37","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(16)30510-1","article-title":"Analysing Data From Patient-Reported Outcome and Quality of Life Endpoints for Cancer Clinical Trials: A Start in Setting International Standards","volume":"17","author":"Bottomley","year":"2016","journal-title":"Lancet Oncol"},{"key":"B38","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(19)30790-9","article-title":"International Standards for the Analysis of Quality-of-Life and Patient-Reported Outcome Endpoints in Cancer Randomised Controlled Trials: Recommendations of the SISAQOL Consortium","volume":"21","author":"Coens","year":"2020","journal-title":"Lancet Oncol"},{"key":"B39","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.1998.16.1.139","article-title":"Interpreting the Significance of Changes in Health-Related Quality-of-Life Scores","volume":"16","author":"Osoba","year":"1998","journal-title":"J Clin Oncol"},{"key":"B40","doi-asserted-by":"publisher","DOI":"10.1007\/s00520-006-0037-6","article-title":"Assessing Cognitive Function in Cancer Patients","volume":"14","author":"Vardy","year":"2006","journal-title":"Support Care Cancer"},{"key":"B41","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdu448","article-title":"Cognitive Function and Fatigue After Diagnosis of Colorectal Cancer","volume":"25","author":"Vardy","year":"2014","journal-title":"Ann Oncol"},{"key":"B42","doi-asserted-by":"publisher","DOI":"10.1007\/s11060-020-03502-y","article-title":"Neurocognitive Functioning and Health-Related Quality of Life in Adult Medulloblastoma Patients: Long-Term Outcomes of the NOA-07 Study","volume":"148","author":"Dirven","year":"2020","journal-title":"J Neuro-Oncol"},{"key":"B43","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1097\/01823246-200112020-00007","article-title":"Longitudinal Assessment of Neurocognitive Function After Coronary-Artery Bypass Surgery","volume":"12","author":"Newman","year":"2001","journal-title":"Cardiopulmon Phys Ther J"},{"key":"B44","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1016\/j.acn.2006.08.013","article-title":"Practice Effects in the Prediction of Long-Term Cognitive Outcome in Three Patient Samples: A Novel Prognostic Index","volume":"22","author":"Duff","year":"2007","journal-title":"Arch Clin Neuropsychol"},{"key":"B45","article-title":"Is\"Chemobrain\" a Transient State? A Prospective Pilot Study Among Persons With Non-Small Cell Lung Cancer","volume":"6","author":"Whitney","year":"2008","journal-title":"J Support Oncol"},{"key":"B46","doi-asserted-by":"publisher","DOI":"10.1186\/1748-717X-7-77","article-title":"Neurocognitive Function Impairment After Whole Brain Radiotherapy for Brain Metastases: Actual Assessment","volume":"7","author":"Tallet","year":"2012","journal-title":"Radiat Oncol"},{"key":"B47","doi-asserted-by":"publisher","DOI":"10.1093\/jnci\/djp386","article-title":"Adverse Symptom Event Reporting by Patients vs Clinicians: Relationships With Clinical Outcomes","volume":"101","author":"Basch","year":"2009","journal-title":"J Natl Cancer Inst"},{"key":"B48","doi-asserted-by":"publisher","DOI":"10.14694\/edbk_156686","article-title":"The Role of Clinical Trial Participation in Cancer Research: Barriers, Evidence, and Strategies","volume":"36","author":"Unger","year":"2016","journal-title":"Am Soc Clin Oncol Educ Book"},{"key":"B49","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.21907","article-title":"Generalizability of Cancer Clinical Trial Results: Prognostic Differences Between Participants and Nonparticipants","volume":"106","author":"Elting","year":"2006","journal-title":"Cancer"},{"key":"B50","doi-asserted-by":"publisher","DOI":"10.1016\/S2213-2600(17)30262-X","article-title":"Icotinib Versus Whole-Brain Irradiation in Patients With EGFR-Mutant Non-Small-Cell Lung Cancer and Multiple Brain Metastases (BRAIN): A Multicentre, Phase 3, Open-Label, Parallel, Randomised Controlled Trial","volume":"5","author":"Yang","year":"2017","journal-title":"Lancet Respir Med"},{"key":"B51","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejca.2011.10.016","article-title":"Outcome, Quality of Life and Cognitive Function of Patients With Brain Metastases From Non-Small Cell Lung Cancer Treated With Whole Brain Radiotherapy Combined With Gefitinib or Temozolomide. A Randomised Phase II Trial of the Swiss Group for Clinical Ca","volume":"48","author":"Pesce","year":"2012","journal-title":"Eur J Cancer"},{"key":"B52","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2010.29.6053","article-title":"Phase III Trial of Prophylactic Cranial Irradiation Compared With Observation in Patients With Locally Advanced Non-Small-Cell Lung Cancer: Neurocognitive and Quality-of-Life Analysis","volume":"29","author":"Sun","year":"2011","journal-title":"J Clin Oncol"},{"key":"B53","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s12885-016-3017-3","article-title":"The Efficacy and Roles of Combining Temozolomide With Whole Brain Radiotherapy in Protection Neurocognitive Function and Improvement Quality of Life of Non-Small-Cell Lung Cancer Patients With Brain Metastases","volume":"17","author":"Deng","year":"2017","journal-title":"BMC Cancer"},{"key":"B54","doi-asserted-by":"publisher","DOI":"10.1016\/S0169-5002(97)00059-7","article-title":"A Dilemma in Analysis: Issues in the Serial Measurement of Quality of Life in Patients With Advanced Lung Cancer","volume":"18","author":"Hollen","year":"1997","journal-title":"Lung Cancer"},{"key":"B55","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/1471-2288-12-96","article-title":"A Review of the Reporting and Handling of Missing Data in Cohort Studies With Repeated Assessment of Exposure Measures","volume":"12","author":"Karahalios","year":"2012","journal-title":"BMC Med Res Method"},{"key":"B56","doi-asserted-by":"publisher","DOI":"10.1001\/jamaoncol.2015.3969","article-title":"Quality of Life Analysis of a Radiation Dose-Escalation Study of Patients With Non-Small-Cell Lung Cancer a Secondary Analysis of the Radiation Therapy Oncology Group 0617 Randomized Clinical Trial","volume":"2","author":"Movsas","year":"2016","journal-title":"JAMA Oncol"}],"container-title":["Frontiers in Oncology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2021.685605\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,6,17]],"date-time":"2021-06-17T08:18:41Z","timestamp":1623917921000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2021.685605\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,6,17]]},"references-count":56,"alternative-id":["10.3389\/fonc.2021.685605"],"URL":"https:\/\/doi.org\/10.3389\/fonc.2021.685605","relation":{},"ISSN":["2234-943X"],"issn-type":[{"value":"2234-943X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,6,17]]},"article-number":"685605"}}